SLU-PP-332
Synthetic ERRα/β/γ pan-agonist (exercise mimetic research chemical)
Mechanism of Action
Synthetic pan-agonist of estrogen-related receptors alpha, beta, and gamma (highest potency at ERRα), orphan nuclear receptors that transcriptionally regulate mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle in skeletal muscle.
Key Benefits
- Increased mitochondrial function and cellular respiration in skeletal muscle cell lines (preclinical)
- Increased type IIa oxidative muscle fiber content and enhanced exercise endurance in mice
- Reduced fat mass and improved insulin sensitivity in diet-induced obese mouse models
- Induces an ERRα-dependent acute aerobic-exercise gene program without physical exercise (mice)
Dosing Protocol
Entirely a research/preclinical compound — genuinely a small molecule, not a peptide. Any vendor 'dosing protocol' for human use is not derived from clinical data and should be treated with corresponding skepticism.
Ideal Candidates
Basic/translational research into ERR pharmacology, exercise mimetics, and metabolic disease models. Not established for human use in any capacity.
Side Effects & Safety
No human safety data exists. Original compound lacks oral bioavailability, limiting translational relevance; a newer analog (SLU-PP-915) was developed specifically to address this.
Regulatory Status
RestrictedNot a peptide — a synthetic small-molecule nuclear receptor agonist. Preclinical (rodent) research only; no human trials, no 503A listing, no regulatory review of any kind. Included here for research-category continuity given how it's marketed in the RUO space, but it does not meet the strict definition of a peptide.
Evidence & Citations
- Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756-771.
- Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240.
- Billon C, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2025;393(1):103787.
- Losby M, et al. The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Mol Pharmacol. 2024;106(4):164-172.
Frequently asked
What is SLU-PP-332?+
SLU-PP-332 (Synthetic ERRα/β/γ pan-agonist (exercise mimetic research chemical)) is a peptide studied for err pan-agonist and exercise mimetic. Synthetic pan-agonist of estrogen-related receptors alpha, beta, and gamma (highest potency at ERRα), orphan nuclear receptors that transcriptionally regulate mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle in skeletal muscle.
What is the dosing protocol for SLU-PP-332?+
Literature commonly references No validated human dosing exists (preclinical/rodent only) (low) to No validated human dosing exists (preclinical/rodent only) (maintenance) via IP (rodent studies); not orally bioavailable in original form, on a n/a — no human protocol established cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of SLU-PP-332?+
Not a peptide — a synthetic small-molecule nuclear receptor agonist. Preclinical (rodent) research only; no human trials, no 503A listing, no regulatory review of any kind. Included here for research-category continuity given how it's marketed in the RUO space, but it does not meet the strict definition of a peptide.
Where can I access SLU-PP-332?+
Research-grade SLU-PP-332 is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.